← Search another drug
PatientPulse · by PatientPartner
Ultomiris ravulizumab
High confidence
~51 public patient conversations, columns, and reviews referenced across forums, disease-specific news sites, and review platforms
Executive intelligence
The signal that moves starts & adherence
72%Positive sentiment in discussion
12,242FDA adverse-event reports
52%Flagged serious
54%Reports name female patients
The single most decision-relevant signal: the 8-week infusion interval is itself a therapeutic benefit patients name as a reason to stay on therapy, making scheduling convenience a genuine adherence driver and a sharp differentiator from Soliris.
- The every-8-week schedule is the top patient-reported reason to choose and stay on Ultomiris, enabling travel, work, and life planning that biweekly Soliris users could not achieve.
- Efficacy satisfaction is extremely high across gMG, PNH, and NMOSD, with many patients describing near-complete symptom resolution, but a small subset reports a symptom-wear-off window at weeks 6-7 that creates anxiety and adherence risk.
- Post-infusion fatigue, joint and muscle pain, and persistent headache are the dominant lived-experience side-effect complaints, even though formal review-site ratings remain exceptional (9.4-9.5 out of 10 on Drugs.com).
- Meningococcal vaccination logistics and the REMS enrollment process add perceived complexity to treatment initiation, but Alexion OneSource patient support receives unsolicited praise and is cited as a meaningful anxiety-reducer.